16th Congress of the Asian Pacific Society of Respirology

3 – 6 November, 2011, Shanghai

www.apsr2011.orgWelcome message from the Honorary Congress PresidentOn behalf of the Local Congress Committee, it is my honor to cordially invite you all to the 16th APSR. In its 16th year, the APSR Congress has been welcomed for the third time to China and we consider it a great honor to host this event, for the first time in Shanghai. The Congress venue will be the Shanghai International Convention Center. The APSR, Chinese Society of Respiratory Diseases and Shanghai Medical Association have joined forces as co-organizers of the Congress to bring together physicians, academics, healthcare professionals and decision makers in the field of respiratory medicine from around the world to discuss emerging issues and exchange ideas on current research and clinical topics in respirology.The Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in respirology, primarily in conditions commonly found in the Asia Pacific region. The meeting will invite many distinguished international speakers who are expected to participate and provide insights and expert opinion on a wide range of topics in pulmonary and respiratory medicine.I hope that you will enjoy the Congress and that your interaction with your colleagues from different countries will stimulate a creative exchange of ideas and will be personally rewarding. I also trust that you will enjoy your visit to the beautiful and exciting city of Shanghai, in November 2011.

Prof. Zhong Nanshan

Honorary Congress President, APSR 2011

Welcome message from the Congress PresidentIt is my great pleasure and honor as Congress President, to welcome you to the 16th Congress of the Asian Pacific Society of Respirology (APSR). The APSR is renowned as a dynamic organization showcasing the breadth and depth of respiratory medicine across the Asia Pacific region. Following the success of the two previous meetings held in China, this year’s congress hosted by Chinese Society of Respiratory Diseases (CSRD) and Shanghai Medical Association, will be held at the Shanghai International Convention Center, in the vibrant and international metropolis of Shanghai. Since its inception and first meeting held in Tokyo in 1988, the congress has gone from strength to strength and we are expecting this year’s meeting to be no exception and continue this momentum to be an outstanding success.Scheduled for the 3 – 6 November 2011, this four-day congress will feature a comprehensive scientific program, including post-graduate courses, lectures and symposia conducted by key note speakers, who are experts in the field of respirology. In addition, oral and poster presentations will provide exposure for researchers, as a platform for academic exchange on exciting new topics currently under investigation. The organizing committee has organized a range of social events and tours to encourage participants to experience the diverse local culture and traditions of the host city.I hope this Congress will be an exciting and productive gathering of respirologists from the Asia Pacific Region and provide an opportunity to share their knowledge, experience and views on current respiratory disease topics, and provide a platform for networking and collaboration between academics and physicians across the region.I would like to thank the APSR 2011 Local Congress Committee for their dedication and support in making this Congress a success and I would also like to thank all participants for their continued interest and involvement in these meetings and look forward to meeting you in November in Shanghai.We invite you to visit the website (www.apsr2011.org) regularly for the latest updates and news about the organization of the Congress.See you in Shanghai in 2011

Prof. Bai Chunxue

Congress President, APSR 2011

各有关单位：

当前，我国政府从监管和科技层面都对临床前药物安全性评价研究给予了高度的重视和支持，在国家高技术发展计划(“863” 计划)和“国家重大新药创制”科技重大专项中，都将临床前药物安全性评价研究列为重要内容；而重视药物安全性评价是新药研发的国际大趋势，提高药物安全水平也是保障人民健康的必然要求。为适应我国创新药物研究与开发的需要，紧密结合我国新药临床前安全评价的GLP要求，进一步增强创新性药物非临床研究中安全性、有效性的研发思路、评价与实践的交流，以应对我国药物安全性评价研究特别是临床前药物毒理学研究面临机遇和挑战。经研究，全国医药技术市场协会于2012年9月3日-6日在上海市举办“药物非临床安全评价关键技术研讨会”。请各有关单位积极派员参加，现将有关事项通知如下：

一、会议时间地点：

时间：2012年9月3日-6日（3日全天报到）

地点：上海市（地点确定直接通知报名者）

二、会议主要交流研讨内容：

1.国内外GLP的现状及展望

2.药物GLP认证检查标准、程序及要求

3.新药早期毒性评价优化筛选系统的建立与应用

4.毒理基因组学技术在新药研发中的应用

5.创新药物安全性研究新思路、新技术与新方法介绍

6.生物技术药物安全性评价关键技术介绍

7.新药非临床安全性评价研究的实验设计、实施与综合评估

8. 药物毒理学研究新思路、新技术与毒性评价新方法

9.药物上市后再评价

10.不同注册分类新药的安全性评价要求及常见问题

11.新药临床前药效学研究技术要求及非临床药效学试验设计

12.新药潜在的肝肾毒性评价

三、参会对象：

药物研究机构及制药企业中从事临床前安全性评价相关工作的人员；药物安全评价机构毒理学试验研究人员；药物非临床试验毒性病理试验研究人员；药品研发机构和制药企业药物研发与产品注册人员；CRO公司从事药物非临床安全性评价相关人员；进出口检验机构的试验研究人员以及其他与非临床安全性评价相关的工作人员等。

四、会议费用：

会务费：1980元/人；费用含专家费、会务费、资料费等；食宿统一安排，费用自理。

五、会议形式说明：

1. 邀请知名专家理论讲解,实例分析,专题讲授,互动答疑。

2. 可采用现场演讲、实物展示、图片展览、多媒体展播、会刊等多种方式对推介相关技术（产品）进行介绍。

3、本次研讨会将面向全国征集与主题相关的学术报告、论文、调研成果，将择优选用并安排会议发言。

4、论文来稿应具有科学性、实用性，且论点鲜明、数据可靠、文字精练通顺，文稿请用word文档（A4纸）电子邮件投递至专用信箱，一般文章以3000～5000字为宜。来稿须列出题目、作者姓名、工作单位、地名（城市）及邮政编码、论文摘要、关键词、正文、主要参考文献。多位作者的署名之间，应用空格隔开。不同工作单位的作者，应在姓名之后标注作者工作单位，并列出工作单位、地名、邮政编码。截稿日期：2012年8月24日。

六、联系方式：

电话：010-51795206 13811915260

传真：010-80115555 转775080

报名邮箱：pharm@263.net 联系人：王旭东

二零一二年七月

附件一：

日程安排表

附件二：

药物非临床安全评价关键技术研讨会回执表